Participants 18 years and older who meet the diagnostic criteria for the basal cell nevus (Gorlin) syndrome will be assigned to receive either Patidegib Gel 2% or Placebo (no active medicine) to apply twice daily for 12 months. The assignment will be made according to sex assigned at birth, age, and number of BCC lesions at the treatment area at Baseline. The primary endpoint is a comparison between the 2 treatment arms of the number of new BCCs at Month 12 compared to Baseline. The BCCs will be imaged and tracked consistently throughout the study to identify new BCCs and to confirm their diagnosis by dermoscopy (handheld instrument with a 15x magnification lens and a cross-polarized light source).

Participants will participate in 15 visits over approximately 14 months (attend 6 in person visits along with 9 phone call visits). In addition, participants will receive study medication to apply twice a day for 12 months and undergo clinical tests at various time points, which include blood tests, ECG, complete questionnaires/diary, skin exam and skin photographs.

Compensation is provided for eligible participants.

This research aims to learn more about your daily thoughts, behaviors, and their impact on social relationships. We want to understand the different qualities of day-to-day thoughts, how these might affect your mood, and how this may influence how you behave in social interactions. We will first ask you to complete a set of structured questionnaires and a brief 30-minute psychological interview via Zoom. This will be followed by a training session in which you will learn how to use your smartphone to track your social interactions and related daily thoughts and behaviors eight times a day for eight days.

You will undergo an initial assessment visit conducted on Zoom, where you will provide informed consent and undergo screening through a brief 30-minute clinical interview. Based on your responses, we will know if you can participate in the study. If eligible, you will be invited to the second part of the study. If so, during the same session, you will then receive a brief half-hour training session reviewing instructions on using a mobile application to complete daily surveys and then complete a series of online questionnaires. When you leave this session, for the next eight days, you will complete eight (approximately 2-minute) questionnaires daily between 10 a.m. and 10 p.m. On the third day, you will attend a compliance check via Zoom to review your progress in the present study.

$20

The study goal is to develop robots that can learn simple games by interviewing humans. The robot interview strategies are represented as Markov Decision Process policies, and are developed offline through robot interactions with simulated interviewees. The investigator can set the simulated interviewee to respond to the robot's queries with different amounts of information. The games include board games like Connect 4, Quarto, and Checkers. The communication between the robot and simulated interviewee is in a formal language like first order logic. After a simulated dialogue, the robot will have more or less knowledge of the game, depending on the conditions of the simulated interviewee. Human subjects will interact with the robots in two ways. First, to test the utility of the new knowledge, human subjects will participate in experiments where they play the game with virtual robots that have learned the game under different conditions. Second, to investigate the kinds of misunderstandings of questions and answers that might arise if the robot could interview a human, we will present subjects with extracts from the formal language dialogues that we have mapped to English in different ways, and ask subjects to imagine how they would express the same meaning in English, or answer questions in different ways, or what sorts of misunderstandings they might imagine in a real dialogue.

This is a drug study that will evaluate how well the investigational drug works compared to a placebo following CAR-T cell therapy. Participants will be required to keep all your scheduled visits, receive drug treatment, blood draws, imaging, and possibly a tumor biopsy.

Participants will be required to receive the study treatments including CAR-T infusion, blook tests, imaging, tumor biopsy, and study medications.

A randomized placebo-controlled study to evaluate the efficacy and safety of VIB4920 in study participants with active lupus nephritis

Patients come for in-person visits at the Penn State Hershey main hospital location. There will be blood draws, physical exams, and questionnaires spread out across 60 weeks.

In contexts where people speak different dialects of the same language, how much overlap is there between the dialects, and what are the genuine grammatical differences? This study explores this question through a series of three experiments examining how people from three different dialects understand a variety of negative sentences (e.g., I didn't eat nothing). The results will contribute to our understanding of linguistic diversity.

Participants will sit at a computer and have their eye movements tracked by a camera as they read or listen to sentences and look at pictures on the screen.

$15 per hour

This study investigates whether persons with aphasia understand and process sentences with vernacular features in a manner similar to more typical populations. Participants will rate sentences on their naturalness and on whether they make sense, and they will also read sentences while we track their eye movements.

In an increasingly global environment, both within the US and abroad, the ability to rapidly gain native-like linguistic competence is a critical asset. The ability to use an L2 in a way that is both expected and recognized by its native speakers is important both to the broad public, and to specific sectors, such as military personnel, that must develop native-like competence in a foreign language in a limited amount of time. The studies conducted under this IRB protocol will examine how learners/speakers of a second language acquire and process multi-word units (e.g., carry a business; run a store) in their second language, and how knowledge from the first language might influence the learning and processing of multi-word units in a second language.

Participants will complete a number of simple tasks on a computer in English and/or in Spanish (depending on language background).

$12/hour (behavioral sessions); $18/hour (EEG sessions); $20 bonus at completion of study when at least 3 behavioral sessions or 2 EEG sessions are required.

This study seeks to verify the findings of the CHARM I pilot study by conducting a multi-center clinical trial. We hypothesize that: • Pancreatic cyst infusion with a specifically designed drug therapy cocktail following normal saline lavage will result in cyst destruction rates that do not significantly differ from those achieved by alcohol-based cyst treatment (ethanol lavage followed by infusion of the same chemotherapeutic cocktail). • The removal of alcohol from the procedure will decrease both serious and minor adverse event rates associated with pancreatic cyst treatment. • There may be molecular markers contained within the fluid of these cystic tumors which identify cysts that are favorable to or resistant to EUS-guided fine needle infusion using this drug combination. As such, we will test all treated cysts for 10 of the best known molecular markers for evaluation in post study analysis. We expect that administering a specifically designed chemotherapeutic cocktail without prior alcohol lavage will result in an equivalent rate of cyst resolution with fewer complications when compared to alcohol. The results of this study will provide important information about the most efficient and safest method for treating premalignant pancreatic cysts, an important step for treating these lesions with a minimally invasive technique and preventing their progression to cancer. Standard alternative treatment options for this patient group (if not taking part in this study) would be ongoing periodic radiographic monitoring with MR or CT imaging waiting for signs of cancer to develop or to consider surgical removal of the affected tissue.

Patients will have to sign the consent form to participate in the trial

We are asking you to take part in this voluntary research study because you have a brain tumor (glioblastoma) that has gotten worse despite first treatment. The purpose of this voluntary research study is to is to learn if the SonoCloud-9 (SC9) implantable device can be used in combination with Carboplatin chemotherapy to help control glioblastoma at recurrence. Neither Sonocloud-9 (SC9) in combination with Carboplatin chemotherapy is not FDA approved.

As part of your routine care, you will be asked to undergo surgery to remove the tumor that has come back. You will be randomized into one of the treatment groups. If you are in the study drug group the surgeon will insert the SonoCloud-9 device (SC9) implant into the skull bone at the end of the tumor resection surgery. If you are in the routine treatment group, the surgeon will close the wound without implanting the SC9 device. The treatment itself will start within 12 to 21 days after the randomization. - If you are in the study drug group you will receive up to 7 doses (every 3 weeks) of Carboplatin at the same time the SonoCloud-9 device is being activated. Further details on the procedures are described below. A brain MRI (Magnetic Resonance Imaging) scan will be performed after the first cycle as part of the research to evaluate opening of the BBB (blood-brain barrier). - If you are in the routine treatment group, you will receive up to 4 doses of Lomustine (every 6 weeks), or, if considered as best appropriate, up to 6 doses of Temozolomide (every 4 weeks). Additional in-person hospital visits or telehealth consultations by video or phone will be performed at regular intervals.

$350.00

Description: This research study is to assess energetic status, reproductive health, and bone health in a population of young exercising men. Secondarily, this study will also explore how diet, fitness, cardiovascular function, eating behaviors, stress, cognitive function, and sleep related to energy and reproductive outcomes in exercising men. Eligible young men (age 18-35) are those who are generally healthy and either a) exercising or b) not exercising.

There will be essentially 5 study visits - The first visit will include informed consent to take part in the study & completion of questionnaires and measurement of anthropometrics. Visit 2 will include tests of your metabolism, a blood draw, a saliva collection, and assessment of diet and physical activity. Visit 3 will be a short visit for a saliva collection. Visit 4 will include tests of stress (a hair sample), body composition, bone health, aerobic and anaerobic fitness, cognitive testing, and reproductive function. Visit 5 will consist of a results meeting and return of wearable devices and logs.

The purpose of this research study is to better understand how leg blood flow is regulated in healthy people and patients with Peripheral Arterial Disease (PAD). It is also being done to examine if a standard-of-care peripheral intervention procedure to improve blood flow to the leg in PAD patients will improve the oxygen delivery and blood flow response to exercise in their legs.

Healthy subjects will participate in 1 visit and perform handgrip and foot (plantar flexion) exercises while several non-invasive measurements are recorded.

You will receive $25 per hour for your participation in this research study

This trial will examine different doses of JANX007 to find the safest dose to treat metastatic castration resistant prostate cancer (mCRPC)

Participants will be required to come to all clinic visits, report any symptoms they are having and all medications they are taking, including over the counter medications.

The purpose of the study is to test how social decisions are affected by possible risk of infection. We aim to examine how choices in a risky social decision-making situation can influenced by viewing images of infection threat (e.g., person with runny nose) vs. images of neutral scenes or other threatening scenes.

There will be one 90-minute in-person visit. Participants will be asked to have electrodes placed on their skin to record their physiological signals, answer questionnaires, and complete a decision-making task on the computer while looking at different images.

$30

The purpose of this study is to examine how individual differences in interoception (the ability to sense, interpret, and act on bodily feelings like hunger, fullness, thirst, hot, cold, etc.) relate to eating behaviors in children ages 7-10 years. Findings will inform whether interventions targeting interoceptive awareness may be helpful for prevention of obesity and related chronic diseases.

Child and parent will attend 2 visits at the Clinical Research Center, about 1-3 weeks apart. At visit 1 (~3 hours) - Your child's height and weight will be measured - Your child's percent body fat will be measured using an x-ray based technology - Your child will wear a heart rate monitor and will complete tasks where they are asked to notice or count their heartbeat - Your child will complete questionnaires via an interview with a researcher - Your child will be asked to drink several glasses of water to measure their stomach sensations - You will complete questionnaires At visit 2 (~2.5 hours) - We will collect 4 saliva samples from your child - Your child will eat a meal and taste snacks - Your child will play brain games on an iPad - You will complete questionnaires

$100

Participants in the PIVOT-006 study will either receive surgical treatment plus cretostimogene or surgical treatment alone.This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by CG0070 vs TURBT for the treatment of patients with IR-NMIBC.The purpose of this study is to see if cretostimogene can reduce the risk of your bladder cancer returning, or coming back as quickly as if you did not receive cretostimogene. People in the study will continue to be monitored by cystoscopy and pathology to see how long it takes for the cancer to return. Who May Be Eligible to Take Part In This Study: People with: • Bladder Cancer that has not invaded the muscle (Non-Muscle Invasive Bladder Cancer) • Intermediate-Risk Disease • Over 18All Treatment: 18All patients will receive surgical treatment on study as part of Standard-of-Care. 50% of patients will receive cretostimogene in addition to surgical treatment. For patients who do not receive cretostimogene, you will be offered cretostimogene if your bladder cancer recurs. The treatment will be instilled into the bladder through a thin tube called a catheter. This will be done 14 times over an 12-month period. Main Meausure: Patients who have recurrence of bladder cancer after receiving surgery plus cretostimogene compared to patients who receive surgery alone.

if you decide to take part in this study and meet all of the requirements, all patients will receive surgical treatment on study as part of Standard-of-Care. 50% of patients will receive cretostimogene in addition to surgical treatment. For patients who do not receive cretostimogene, you will be offered cretostimogene if your bladder cancer recurs. You will receive 6 treatments, once per week for 6 weeks in a row. The treatment will be instilled into the bladder through a thin tube called a catheter. This will be done 14 times over an 12-month period. There will be up to 16 visits with blood draw and/or urine colelction. As a part of screening, efficacy and follow up for this study, you might have to have cystoscopy ( up to 6), urine cytology (up to 6), TUBRT or vladder mapping or CT urogram over a 3 year month period.

To evaluate the effect of cabozantinib in combination with avelumab on OS compared to avelumab alone in patients with mUC who did not progress during first-line platinum-based chemotherapy therapy, i.e. patients who had CR, PR or SD after completion of first line platinum-based chemotherapy.

Patients will be expected to come to all clinic appointments, have labs drawn on the first day of every cycle, take medications as prescribed, return all empty pill bottles and diary, and call the clinic with questions.

In this project, we aim to extend the capabilities of smart-speakers (such as Amazon Alexa, Google Home, Siri, etc.) to support more engaging interactions with their users. Specifically, we would like to make the future of smart-speakers more conversational. One of the key aspects in developing a conversation is to be an active listener; showing interest in the speaker and allowing them to extend their turn in talk. In this study we investigate how smart-speakers can become better listeners by incorporating some of the human-human conversational features of active listening. Our question is, how can smart-speakers extend the users' turn in talk by being better listeners?

A clinical trial for adults with Muscle Invasive Bladder Cancer. The study is looking at alternative treatments for those persons who cannot tolerate certain forms of chemotherapy.

This protocol contains two portions. The safety run in (SRI) and the main portion of the trial. The SRI will take place over three cycles of treatment prior to having cystectomy or 9 cycles if you have had a previous cystectomy. The main study will have the same schedule of activities. The only difference between the two is the SRI will look at how safe the drug combinations are and the main trial will look at how effective they are on treating muscle invasive bladder cancer.,

We used a combination of ecological modeling, procedural modeling, and virtual reality to provide an embodied experience of “walking through the forests of the future”. This study will provide empirical evidence of the effectiveness of this immersive experience based on users’ feedbacks on different kinds of tools we developed.

Clinical trial on the treatment of persons who are diagnosed with Lung Cancer.

Participants in this study will undergo screening tests and procedures to determine whether you are eligible to participate with the research study. If you meet the requirements to participate with the study, you be given Brigatinib by mouth each day for 7 days. If you do not experience any intolerable side effects while taking Brigatinib, you will receive an increased dose starting on Day 8 and take Brigatinib continuously each day thereafter. Bevacizumab will be given intravenously (IV) on Day 8 in combination with Brigatinib. The first 28 days of treatment is called Cycle 1. Starting Cycle 2 and thereafter, one cycle will consist of 21 days. Bevacizumab will be given on Day 1 every 21 days starting Cycle 2. Participation is expected to last until your disease worsens or you decide you no longer want to participate in the study. There will be a follow-up visit within 30 days of treatment discontinuation. The study team will check in with you every three months after this final visit to see how you are doing. If you decide to take part, this is what will happen: Since we are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects in participants that have Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLS), not everyone who participates in this research study will receive the same dose of the study drug. The dose you get will depend on the number of participants who have been enrolled in the study before you and how well they have tolerated their doses. If you take part in this research study, you will be given a drug diary. You will be asked to document information in the drug diary about the study drug you are being asked to take. If you take part in this research, study you will be given a study calendar. Information about what to expect during and between study visits will be included in the study calendar.

The purpose of the first part of this study is to compare the usual treatment of a standard-dose radiation given over 6 weeks with cisplatin chemotherapy to a reduced-dose radiation given over either 6 weeks with cisplatin or 5 weeks with the immunotherapy drug, nivolumab. A lower dose of radiation as compared to the usual radiation treatment dose could be as effective in lengthening the time without your cancer getting worse. Nivolumab with reduced-dose radiation may or may not be as effective in lengthening the time without your cancer getting worse. This study will help the study doctors find out if this different approach is the same or worse than the usual approach.

The purpose of the first part of this study is to compare the usual treatment of a standard-dose radiation given over 6 weeks with cisplatin chemotherapy to a reduced-dose radiation given over either 6 weeks with cisplatin or 5 weeks with the immunotherapy drug, nivolumab. A lower dose of radiation as compared to the usual radiation treatment dose could be as effective in lengthening the time without your cancer getting worse. Nivolumab with reduced-dose radiation may or may not be as effective in lengthening the time without your cancer getting worse. This study will help the study doctors find out if this different approach is the same or worse than the usual approach.

This research is being done to study the deterioration of the central olfactory system (sense of smell system) in the brains of patients diagnosed with H&Y stage 1 or 2 Parkinson’s disease compared to that of healthy volunteers.

In this study, you will receive a clinical evaluation and an MRI examination. After that, you will be followed every 12 months for up to 4 years.

up to a total of $250.00.

The purpose of the study is to determine the effects of amiloride on the blood pressure response during exercise, and exercise tolerance in patients with PAD and healthy controls.

There will be 3 in-person visits. You will take a capsule of amiloride or placebo before visits 2 and 3 and blood pressure, heart rate and other physiological measurements will be recorded.

You will receive $25 per hour for your participation in this research study

Sound symbolism is the idea that the sound of a word alone can convey its meaning. Aphasia is a language impairment, occurring most often as a result of a stroke. There is some evidence that sound-symbolic language is preserved in stroke patients. Studies in this protocol will investigate the extent to which this is so, and whether sound-symbolic language could be a rehabilitation strategy for aphasia.

We will ask you to listen to real words and non-words, or look at pictures of objects, and make judgements about them. We may also ask you to complete some tests of language ability. The total time commitment may be up to four hours but will be split into two sessions.

Amount varies depending on the study

The purpose of this study is to better understand how human teams with non-human virtual agent team members operate and function.

If you agree to be in this study, you will be fitted to sensors that will measure your neurophysiological (i.e., brain, cardiac, and respiratory) signals while you complete group tasks in person or in virtual reality. This interaction will be recorded and coded. You will also be asked to complete several questionnaires about your demographics, behaviors, and emotions.

$40

The purpose of this research study is to learn about how humans provide corrections to robot movements when the robot makes mistakes while performing a task. Understanding the intent of humans can inform how we incorporate the information provided by that interaction into machine learning algorithms that improve the robot’s task performance in future.

Participants will observe the robot performing three different tasks. The robot will place a peg in a hole, pickup and pour a cup, and draw and erase an image on a whiteboard. The robot may or may not make mistakes while performing these tasks. Mistakes may be minor or may be significant such as colliding with an object or the work table. Participants will be asked to correct the robot’s mistake by moving the robot arm or stopping the task execution altogether by hitting a red stop button. After observing the robot perform each task several times, you will be asked to demonstrate a new task to the robot. The robot will then try to replicate your demonstration and you may choose to provide corrections to improve the robot’s execution of the task anytime you think it is making a mistake or not performing well enough.

20

Social network site (SNS) use has been very integrated into our daily practices. The distinctions between offline and online social relationship management become blurred with the mediation of SNSs. We are interested in how people perceive and use SNS and engage in social relationship management, such as self-disclosure or privacy management. Users may appropriate technological features to meet their own needs and such practices may be different from how others use the sites. The discrepancy of usage may in turn influence social relationship maintenance.

This study is designed to better understand how people complete complicated tasks, and the best ways in which to measure their performance. If you agree to the study, you will be asked to fill out questionnaires on your thoughts, feelings, and behaviors; take a short interview on the same; and complete brain teasers and computerized tests of attention and learning.

There are several steps to determining whether you are a good fit for the study. If you agree to be in the study, then we will send you a link to complete online questionnaires (~10 min) on your thoughts, feelings, and behaviors. If you are a good fit, then we will schedule a laboratory visit in Moore Building at the University Park campus (maximum length of time = 3 hours). During that visit you will complete an interview and more questionnaires, brain teasers, and computerized tests of attention and learning. The visit will be video recorded for quality assurance.

$50

This is a study of the drug DFMO (difluoromethylornithine) for medulloblastoma that has returned or not responded to treatment. DFMO is an oral drug that inhibits a certain enzyme (protein) in blood which is associated with a bad outcome in neuroblastoma cases. Cancer cells have pathways that drive the cancer to grow and DFMO targets the specific pathway of this enzyme to turn these cells off.

You will have exams, tests, and procedures while on the study to evaluate whether you can participate in the study and how you are doing while on the study. These include physical exams, blood tests, urine tests, bone marrow aspirate and biopsies, heart tests, hearing tests, and imaging evaluations such as MRI of your brain and spine. You will receive treatment on this study for a total of about 2 years. After treatment, you will have follow-up examinations and medical tests. We would like to continue to find out about your health for about 5 years after you complete the study.